Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk

Authors: ZhiZhen Wang, Wencheng Zhang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

The x-ray repair cross-complementing group 3 (XRCC3), a member of DNA repair genes, plays a critical role in the maintenance of genome stability by homologous recombination repair for DNA double-strand breaks. The polymorphism of XRCC3 Thr241Met has been indicated to be involved in the development of some cancers, but previous individual studies on the association between XRCC3 Thr241Met polymorphism and colorectal cancer (CRC) risk have yielded conflicting and inconclusive results. To shed some light on the contradictory findings and improve our understanding of the pathogenesis of CRC, we carried out this updated meta-analysis by pooling all available publications. Databases including PubMed, Embase, Web of Science and China National Knowledge Infrastructure were searched for relevant publications. The odds ratios (ORs) with the corresponding 95 % confidence intervals (95 % CIs) were calculated to estimate the strength of the association between XRCC3 Thr241Met polymorphism and CRC risk. A total of 15 case–control studies involving 4,475 cases and 6,373 controls were included. Overall, the pooled ORs for the meta-analysis of total included studies showed no statistically significant association of XRCC3 Thr241Met polymorphism with CRC risk in any genetic model (ORMet allele vs. Thr allele = 1.17, 95 % CI 0.97–1.42, P OR = 0.102; ORMetMet vs. ThrThr = 1.32, 95 % CI 0.93–1.87, P OR = 0.121; ORThrMet vs. ThrThr = 1.17, 95 % CI 0.94–1.45, P OR = 0.150; ORMetMet + ThrMet vs. ThrThr = 1.20, 95 % CI 0.96–1.51, P OR = 0.114; ORMetMet vs. ThrThr + ThrMet = 1.37, 95 % CI 0.98–1.93, P OR = 0.065). However, in subgroup analyses stratified by source of controls and ethnicity, the XRCC3 Thr241Met polymorphism was associated with an elevated risk of CRC in the hospital-based case–control studies and the Asian population. Sensitivity analysis indicated that the findings were unlikely due to chance. This meta-analysis suggests that the XRCC3 Thr241Met polymorphism may modify the risk of CRC, particularly in Asians.
Literature
1.
Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int. 2012;2012:509348.PubMed
2.
Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRef
3.
Goel A, Boland CR. Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 2010;26:47–52.PubMedCrossRef
4.
Yu Y, Wang W, Zhai S, Dang S, Sun M. IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Mol Biol Rep. 2012;39:8457–63.PubMedCrossRef
5.
Xu D, Yan S, Yin J, Zhang P. Null genotype of GSTT1 contributes to colorectal cancer risk in Asian populations: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2011;12:2279–84.PubMed
6.
Liu Y, Qin H, Zhang Y, Shi T, Liu B, Sun Y, et al. P53 codon 72 polymorphism and colorectal cancer: a meta-analysis of epidemiological studies. Hepatogastroenterology. 2011;58:1926–9.PubMed
7.
Jiang Z, Li C, Xu Y, Cai S. A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk. Int J Colorectal Dis. 2010;25:169–80.PubMedCrossRef
8.
Abdel-Rahman SZ, El-Zein RA. Evaluating the effects of genetic variants of DNA repair genes using cytogenetic mutagen sensitivity approaches. Biomarkers. 2011;16:393–404.PubMedCrossRef
9.
Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed
10.
Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164:297–302.PubMedCrossRef
11.
Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999;13:2633–8.PubMedCrossRef
12.
Sun H, Qiao Y, Zhang X, Xu L, Jia X, Sun D, et al. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a meta-analysis. Cancer Sci. 2010;101:1777–82.PubMedCrossRef
13.
Economopoulos KP, Sergentanis TN. XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;121:439–43.PubMedCrossRef
14.
Han S, Zhang HT, Wang Z, Xie Y, Tang R, Mao Y, et al. DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case–control studies. Eur J Hum Genet. 2006;14:1136–44.PubMedCrossRef
15.
Zhao Y, Deng X, Wang Z, Wang Q, Liu Y. Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 2012;13:665–9.PubMedCrossRef
16.
Gil J, Ramsey D, Stembalska A, Karpinski P, Pesz KA, Laczmanska I, et al. The C/A polymorphism in intron 11 of the XPC gene plays a crucial role in the modulation of an individual's susceptibility to sporadic colorectal cancer. Mol Biol Rep. 2012;39:527–34.PubMedCrossRef
17.
Canbay E, Cakmakoglu B, Zeybek U, Sozen S, Cacina C, Gulluoglu M, et al. Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population. Curr Med Res Opin. 2011;27:1295–302.PubMedCrossRef
18.
Krupa R, Sliwinski T, Wisniewska-Jarosinska M, Chojnacki J, Wasylecka M, Dziki L, et al. Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer—a case control study. Mol Biol Rep. 2011;38:2849–54.PubMedCrossRef
19.
Wang J, Zhao Y, Jiang J, Gajalakshmi V, Kuriki K, Nakamura S, et al. Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case–control study in an Indian population. J Cancer Res Clin Oncol. 2010;136:1517–25.PubMedCrossRef
20.
Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.PubMedCrossRef
21.
Skjelbred CF, Saebo M, Wallin H, Nexo BA, Hagen PC, Lothe IM, et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer. 2006;6:67.PubMedCrossRef
22.
Stern MC, Siegmund KD, Corral R, Haile RW. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol Biomarkers Prev. 2005;14:609–15.PubMedCrossRef
23.
Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, Hunter DJ. XRCC2 and XRCC3 polymorphisms are not associated with risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2004;13:1090–1.PubMed
24.
Krupa R, Blasiak J. An association of polymorphism of DNA repair genes XRCC1 and XRCC3 with colorectal cancer. J Exp Clin Cancer Res. 2004;23:285–94.PubMed
25.
Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer. 2003;89:333–7.PubMedCrossRef
26.
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case–control study in Taiwan. BMC Cancer. 2005;5:12.PubMedCrossRef
27.
Improta G, Sgambato A, Bianchino G, Zupa A, Grieco V, La Torre G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case–control study in a Southern Italian population. Anticancer Res. 2008;28:2941–6.PubMed
28.
Zhang JW, Meng XL. Genetic polymorphism of DNA repair gene XRCC3 and colon cancer risk. Acta Universitatis Medicinalis Anhui. 2011;46:1172–4 [Article in Chinese].
29.
Jin MJ. Molecular epidemiology study on colorectal cancer susceptibility. Doctoral Dissertation of Zhejiang University. 2007. [Article in Chinese]
30.
Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed
31.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
32.
33.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
34.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
35.
Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.PubMedCrossRef
36.
Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2012. doi:10.​1038/​tpj.​2012.​31
37.
Liu Y, Chen H, Chen L, Hu C. Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population. Hepatogastroenterology. 2012;59:977–80.PubMed
38.
Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 2011;11:214–26.PubMedCrossRef
39.
Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Diaz-Rubio E, et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer. 2008;44:1229–37.PubMedCrossRef
40.
Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. 2008;8:278–88.PubMedCrossRef
41.
Yeh CC, Hsieh LL, Tang R, Chang-Chieh CR, Sung FC. MS-920: DNA repair gene polymorphisms, diet and colorectal cancer risk in Taiwan. Cancer Lett. 2005;224:279–88.PubMedCrossRef
42.
Jin MJ, Chen K, Song L, Fan CH, Chen Q, Zhu YM, et al. The association of the DNA repair gene XRCC3 Thr241Met polymorphism with susceptibility to colorectal cancer in a Chinese population. Cancer Genet Cytogenet. 2005;163:38–43.PubMedCrossRef
43.
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomed Sci. 2007;14:183–93.PubMedCrossRef
44.
Reeves SG, Meldrum C, Groombridge C, Spigelman A, Suchy J, Kurzawski G, et al. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome. Cancer Epidemiol. 2012;36:183–9.PubMedCrossRef
45.
Romanowicz-Makowska H, Brys M, Forma E, Maciejczyk R, Polac I, Samulak D, et al. Single nucleotide polymorphism (SNP) Thr241Met in the XRCC3 gene and breast cancer risk in Polish women. Pol J Pathol. 2012;63:121–5.PubMed
46.
Kiyohara C. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. J Epidemiol. 2000;10:349–60.PubMedCrossRef
47.
Jiang H, Tang Y, Garg HK, Parthasarathy DK, Torregrossa AC, Hord NG, et al. Concentration- and stage-specific effects of nitrite on colon cancer cell lines. Nitric Oxide. 2012;26:267–73.PubMedCrossRef
48.
Cross AJ, Ferrucci LM, Risch A, Graubard BI, Ward MH, Park Y, et al. A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res. 2010;70:2406–14.PubMedCrossRef
Metadata
Title
Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk
Authors
ZhiZhen Wang
Wencheng Zhang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0639-1

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Review

Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir

Research Article

Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients

Research Article

The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis

Research Article

Association between epidermal growth factor gene rs4444903 polymorphism and risk of glioma

Research Article

Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA

Research Article

Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits